{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:04:20Z","timestamp":1790071460293,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>LRRK2\u2010Parkinson's disease (LRRK2\u2010PD) is biologically heterogeneous with approximately 30% lacking aggregated alpha synuclein (\u03b1Syn) in cerebrospinal fluid by seed amplification assay (SAA). Prior work has suggested slower progression in LRRK2\u2010PD compared to sporadic PD (sPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to assess how LRRK2\u2010PD with \u03b1Syn aggregates on SAA (S+ LRRK2\u2010PD) compares to S+ sPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from the Parkinson's Progression Markers Initiative were used to compare S+ LRRK2\u2010PD and S+ sPD cohorts propensity score\u2010matched on age, disease duration, sex and levodopa equivalent dose (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200979 per cohort). Baseline clinical and biological features and 4\u2010year longitudinal features were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, S+ LRRK2\u2010PD participants had lower motor scores and dopaminergic deficit. Among measures showing within group progression, longitudinal trajectories did not differ significantly between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Longitudinal clinical progression of S+ LRRK2\u2010PD and sPD in the PPMI study is similar despite differences in baseline features.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.70640","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:43:59Z","timestamp":1776663839000},"page":"2216-2224","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Progression in Alpha\u2010Synuclein Positive\n                    <scp>LRRK2<\/scp>\n                    \u2010\n                    <scp>PD<\/scp>\n                    and Sporadic Parkinson's Disease: A Longitudinal Analysis"],"prefix":"10.1002","volume":"13","author":[{"given":"Lucy A.","family":"Morse","sequence":"first","affiliation":[{"name":"Department of Neurology Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-5741","authenticated-orcid":false,"given":"Seung Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health University of Iowa  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gochanour","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health University of Iowa  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David\u2010Erick","family":"Lafontant","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of Public Health University of Iowa  Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana M.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana M.","family":"Merchant","sequence":"additional","affiliation":[{"name":"Department of Neurology Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Wendelberger","sequence":"additional","affiliation":[{"name":"Berry Consultants  Austin TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Simuni","sequence":"additional","affiliation":[{"name":"Department of Neurology Northwestern University Feinberg School of Medicine  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Parkinson's Progression Markers Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00109-6"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.30085"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.11.005"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0617-y"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51776"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.2704"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaf103"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4019"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318227042d"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70117-0"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/pr13113448"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105866"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28206"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.644"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-022-00787-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","unstructured":"MarekK.The Parkinson's Progression Markers Initiative (PPMI) Clinical\u2010 Establishing a Deeply Phenotyped PD Cohort AM 3.2; [Internet]. protocols.io [updated Apr 18 2024; cited 2025 Oct 6]. Available from:https:\/\/doi.org\/10.17504\/protocols.io.n92ldmw6ol5b\/v2.","DOI":"10.17504\/protocols.io.n92ldmw6ol5b\/v2"},{"key":"e_1_2_11_18_1","unstructured":"Parkinson's Progression Markers Initiative.Study cohorts. PPMI [Internet]. [cited 2025 Sept 26]; Available from:https:\/\/www.ppmi-info.org\/study-design\/study-cohorts."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02872-9"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02871-w"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00881-9"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70640","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:17:42Z","timestamp":1790068662000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/mdc3.70640"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70640","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}